A Long-term Trial of EB-1020 in Adult Patients With ADHD
NCT06926829
·
clinicaltrials.gov ↗
PHASE3
Phase
RECRUITING
Status
180
Enrollment
INDUSTRY
Sponsor class
Conditions
Attention Deficit Hyperactivity Disorder (ADHD)
Interventions
DRUG:
EB-1020 (Centanafadine) 164.4 mg
DRUG:
EB-1020 (Centanafadine) 328.8 mg
Sponsor
Otsuka Pharmaceutical Co., Ltd.